Jump to Main Content
Sedative and cardiopulmonary effects of buprenorphine and xylazine in horses
- Cruz, Fernando S.F., Carregaro, Adriano B., Machado, Melissa, Antonow, Romulo R.
- Canadian journal of veterinary research 2011 v.75 no.1 pp. 35-41
- adults, ataxia (disorder), blood gases, body weight, buprenorphine, gastrointestinal motility, gastrointestinal system, heart rate, horses, intravenous injection, sedation, sedatives, sodium chloride, xylazine
- This study investigated the sedative, cardiopulmonary, and gastrointestinal effects produced by buprenorphine and xylazine given in combination to horses. Six healthy adult horses underwent 4 randomized treatments, with an interval of 1 wk between treatments. A control group was given a saline solution intravenously (IV) and the experimental groups received buprenorphine [10 μg/kg bodyweight (BW)] in combination with 1 of 3 different doses of xylazine: 0.25 mg/kg BW (BX25), 0.50 mg/kg BW (BX50), or 0.75 mg/kg BW (BX75), all of them by IV. Cardiopulmonary parameters were evaluated for 120 min after the drugs were administered and intestinal motility was observed for 12 h after treatment. Sedation was found to be dose-dependent in all groups receiving buprenorphine and xylazine and it was observed that the heart rate decreased in the first 5 min and increased at the end of the sedation period. Arterial blood gas tension analyses showed minimal alterations during the experiment. Gastrointestinal hypomotility was observed for up to 8 h. The combination of buprenorphine and 0.50 mg/kg BW of xylazine (BX50) provided a 30-minute period of sedation without intense ataxia and maintained cardiopulmonary parameters within acceptable limits for the species.